• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美西林在健康受试者中的药代动力学。

Pharmacokinetics of mecillinam in health subjects.

作者信息

Gambertoglio J G, Barriere S L, Lin E T, Conte J E

出版信息

Antimicrob Agents Chemother. 1980 Dec;18(6):952-6. doi: 10.1128/AAC.18.6.952.

DOI:10.1128/AAC.18.6.952
PMID:6263180
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC352996/
Abstract

Mecillinam is an amidino penicillinate derivative with a broad spectrum of activity against many gram-negative bacilli. Moreover, marked in vitro synergy against these organisms occurs when mecillinam is combined with other beta-lactam antibiotics. The purpose of this study was to determine the pharmacokinetic disposition of this antibiotic. A single dose of 10 mg/kg was administered to 12 healthy volunteers as a 15-min intravenous infusion. Multiple plasma and urine samples were collected at frequent intervals for 8 and 24 h, respectively. Plasma samples were assayed for mecillinam by using a specific high-pressure liquid chromatographic assay developed in our laboratory. Peak plasma levels ranged from 34 to 80 micrograms/ml, and after 4 h, plasma levels were 0.7 to 1.9 microgram/ml. The mean terminal plasma half-life was 51.1 +/- 8.6 min. The mean steady-state volume of distribution was calculated to be 0.23 +/- 0.04 liter/kg. The mean plasma and renal clearances were 3.5 +/- 0.4 and 2.5 +/- 0.4 ml/min per kg, respectively. The mean percentage of the dose excreted unchanged in the urine at 4 h was 67 +/- 5%; 71 +/- 6% was recovered in 24 h. Urine concentrations at 4 h were far above the minimum inhibitory concentration for susceptible gram-negative organisms.

摘要

美西林是一种脒基青霉素酸盐衍生物,对多种革兰氏阴性杆菌具有广谱活性。此外,当美西林与其他β-内酰胺类抗生素联合使用时,对这些微生物会产生显著的体外协同作用。本研究的目的是确定这种抗生素的药代动力学特征。对12名健康志愿者以15分钟静脉输注的方式给予10mg/kg的单剂量药物。分别在8小时和24小时内频繁采集多个血浆和尿液样本。使用我们实验室开发的特定高压液相色谱法测定血浆样本中的美西林。血浆峰值水平在34至80微克/毫升之间,4小时后,血浆水平为0.7至1.9微克/毫升。平均终末血浆半衰期为51.1±8.6分钟。计算得出平均稳态分布容积为0.23±0.04升/千克。平均血浆清除率和肾脏清除率分别为3.5±0.4和2.5±0.4毫升/分钟/千克。4小时时尿液中以原形排泄的药物剂量平均百分比为67±5%;24小时内回收率为71±6%。4小时时尿液浓度远高于敏感革兰氏阴性菌的最低抑菌浓度。

相似文献

1
Pharmacokinetics of mecillinam in health subjects.美西林在健康受试者中的药代动力学。
Antimicrob Agents Chemother. 1980 Dec;18(6):952-6. doi: 10.1128/AAC.18.6.952.
2
Multiple-dose pharmacokinetics of amdinocillin in healthy volunteers.氨比西林在健康志愿者中的多剂量药代动力学
Antimicrob Agents Chemother. 1982 Jan;21(1):54-7. doi: 10.1128/AAC.21.1.54.
3
Pharmacokinetics of amdinocillin in healthy adults.氨比西林在健康成年人中的药代动力学。
Antimicrob Agents Chemother. 1983 Jun;23(6):827-30. doi: 10.1128/AAC.23.6.827.
4
Amdinocillin pharmacokinetics. Simultaneous administration with cephalothin and cerebrospinal fluid penetration.
Am J Med. 1983 Aug 29;75(2A):54-9. doi: 10.1016/0002-9343(83)90094-3.
5
Pharmacokinetics of amdinocillin and pivamdinocillin in normal volunteers.氨比西林和匹氨西林在正常志愿者体内的药代动力学。
Am J Med. 1983 Aug 29;75(2A):60-4. doi: 10.1016/0002-9343(83)90095-5.
6
Pharmacokinetics of bacmecillinam and pivmecillinam in volunteers.巴美西林和匹美西林在志愿者体内的药代动力学。
Eur J Clin Pharmacol. 1982;23(3):249-52. doi: 10.1007/BF00547563.
7
Single-dose kinetics and dosage of mecillinam in renal failure and haemodialysis.美西林在肾衰竭和血液透析患者中的单剂量动力学及剂量研究
Clin Pharmacokinet. 1984 Jul-Aug;9(4):364-70. doi: 10.2165/00003088-198409040-00006.
8
Urinary excretion of mecillinam by volunteers receiving film-coated tablets of pivmecillinam hydrochloride.接受盐酸匹美西林薄膜包衣片的志愿者对美西林的尿排泄情况。
Chemotherapy. 1979;25(1):1-4. doi: 10.1159/000237814.
9
Clinical pharmacology of mecillinam in calves.美西林在犊牛中的临床药理学
J Vet Pharmacol Ther. 1986 Dec;9(4):385-93. doi: 10.1111/j.1365-2885.1986.tb00059.x.
10
Plasma concentrations and excretion of mecillinam after oral administration of pivmecillinam in elderly patients.
J Antimicrob Chemother. 1978 May;4(3):241-6. doi: 10.1093/jac/4.3.241.

引用本文的文献

1
Pharmacokinetic/Pharmacodynamic Determination of Systemic MIC Breakpoints for Intermittent, Extended, and Continuous Infusion Dosage Regimens of Mecillinam.美西林间歇、延长和持续输注给药方案的全身最低抑菌浓度(MIC)断点的药代动力学/药效学测定
Microbiol Spectr. 2023 Jan 30;11(2):e0344122. doi: 10.1128/spectrum.03441-22.
2
Assessing Clinical Potential of Old Antibiotics against Severe Infections by Multi-Drug-Resistant Gram-Negative Bacteria Using In Silico Modelling.利用计算机模拟评估旧抗生素对多重耐药革兰氏阴性菌所致严重感染的临床潜力
Pharmaceuticals (Basel). 2022 Nov 30;15(12):1501. doi: 10.3390/ph15121501.
3
Amdinocillin (Mecillinam) resistance mutations in clinical isolates and laboratory-selected mutants of Escherichia coli.临床分离株及实验室筛选的大肠杆菌突变体中氨比西林(美西林)耐药性突变
Antimicrob Agents Chemother. 2015 Mar;59(3):1718-27. doi: 10.1128/AAC.04819-14. Epub 2015 Jan 12.
4
Applications of minimal physiologically-based pharmacokinetic models.最小生理药代动力学模型的应用。
J Pharmacokinet Pharmacodyn. 2012 Dec;39(6):711-23. doi: 10.1007/s10928-012-9280-2. Epub 2012 Nov 23.
5
Pharmacokinetics of amdinocillin in healthy adults.氨比西林在健康成年人中的药代动力学。
Antimicrob Agents Chemother. 1983 Jun;23(6):827-30. doi: 10.1128/AAC.23.6.827.
6
Pharmacokinetics of bacmecillinam and pivmecillinam in volunteers.巴美西林和匹美西林在志愿者体内的药代动力学。
Eur J Clin Pharmacol. 1982;23(3):249-52. doi: 10.1007/BF00547563.
7
Multiple-dose pharmacokinetics of amdinocillin in healthy volunteers.氨比西林在健康志愿者中的多剂量药代动力学
Antimicrob Agents Chemother. 1982 Jan;21(1):54-7. doi: 10.1128/AAC.21.1.54.
8
Pharmacokinetics of intravenous amdinocillin in healthy subjects and patients with renal insufficiency.健康受试者及肾功能不全患者静脉注射氨比西林的药代动力学
Antimicrob Agents Chemother. 1985 Jul;28(1):46-50. doi: 10.1128/AAC.28.1.46.
9
Method of evaluating effects of antibiotics on bacterial biofilm.评估抗生素对细菌生物膜作用效果的方法。
Antimicrob Agents Chemother. 1987 Oct;31(10):1502-6. doi: 10.1128/AAC.31.10.1502.
10
The pharmacokinetics of mecillinam and pivmecillinam in pregnant and non-pregnant women.美西林和匹美西林在孕妇和非孕妇中的药代动力学。
Br J Clin Pharmacol. 1992 Jun;33(6):629-33. doi: 10.1111/j.1365-2125.1992.tb04092.x.

本文引用的文献

1
Synergy of mecillinam (FL1060) with penicillins and cephalosporins against Proteus and Klebsiella, with observations on combinations with other antibiotics and against other bacterial species.美西林(FL1060)与青霉素及头孢菌素对变形杆菌和克雷伯菌的协同作用,以及与其他抗生素联合应用及对其他细菌种类的观察。
Antimicrob Agents Chemother. 1976 Apr;9(4):701-5. doi: 10.1128/AAC.9.4.701.
2
Pharmacokinetic studies with mecillinam and pivmecillinam.美西林和匹美西林的药代动力学研究。
Chemotherapy. 1975;21(3-4):146-66. doi: 10.1159/000221856.
3
Bacteriology and pharmacokinetics of the new amidino penicillin-mecillinam.
J Antimicrob Chemother. 1976 Mar;2(1):61-9. doi: 10.1093/jac/2.1.61.
4
Mecillinam serum levels following intravenous injection: a comparison with pivmecillinam.
J Antimicrob Chemother. 1977 Jul;3 Suppl B:83-8. doi: 10.1093/jac/3.suppl_b.83.
5
Noncompartmental determination of the steady-state volume of distribution.稳态分布容积的非房室测定
J Pharm Sci. 1979 Aug;68(8):1071-4. doi: 10.1002/jps.2600680845.
6
Pharmacokinetics of pivmecillinam.匹美西林的药代动力学。
Br J Clin Pharmacol. 1977 Jun;4(3):267-73. doi: 10.1111/j.1365-2125.1977.tb00711.x.
7
Pharmacokinetic studies with mecillinam and pivmecillinam.美西林和匹美西林的药代动力学研究。
J Antimicrob Chemother. 1977 Jul;3 Suppl B:71-81. doi: 10.1093/jac/3.suppl_b.71.